The influence of alfuzosin monotherapy on the sexual function of patients with benign prostatic hyperplasia in real clinical practice (results of a Russian multicenter study)

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Introduction. The current armamentarium of drugs for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) is diverse and includes both monotherapy and combination therapy. Indirect and limited direct comparisons have demonstrated that all alpha-1-blockers (a1-ABs) have similar efficacy when used at appropriate doses. Differences in tropism to the prostate of modern a1-ABs are largely responsible for the severity of their side effects, mainly negative influence on sexual function and cardiovascular system. Aim. To evaluate the influence of Alfuprost® MR 10 mg once daily on sexual function in patients with LUTS due to BPH during 3-months therapy in real clinical practice. The secondary endpoint was an effect on systolic, diastolic blood pressure (BP) and heart rate. Materials and methods. A total of 537 men with LUTS/BPH were included in the study by urologists from 21 outpatient departments of the Russian Federation. The follow-up included 3 visits: visit of inclusion in the program of patients with a previously prescribed drug of Alfuprost® MR in a dosage of 10 mg once a day (visit "0"), visit 1 at 30 days (±5 days) later, and visit 2 at 90 days (±5 days) after inclusion in the study. At each visit, evaluation of complaints and physical examination was performed. In addition, patients completed questionnaires: International prostate symptom score (IPSS) and quality of life (QoL) index; the full version of the International Index of Erectile Function (IIEF) questionnaire; the Likert scale for the patient and for the physician. Also, laboratory and instrumental studies used in routine clinical practice were recorded: total prostate specific antigen (PSA) in serum; ultrasound examination (US) of the bladder; transrectal ultrasound examination (TRUS) of the prostate; uroflowmetry (maximum urine flow rate (Qmax)); measurement of systolic and diastolic BP; measurement of heart rate. Results: after 3 months of therapy with Alfuprost® MR in a dosage of 10 mg once a day, significant (p<0.05) improvement of all urodynamic parameters was documented, including a decrease in the average IPSS score by 55% and improvement of quality of life by 2.46 points (on the QoL index); increase of Qmax by 53%; reduction of the average postvoid residual to normal values. In addition to a significant improvement in the quality of urination, changes in sexual function were also positive. Thus, the average total IIEF score increased significantly (p<0,05) from 45.35 to 53.18 points. When considering specific domains of male sexual function, positive dynamics in all domains was noted: overall improvement of orgasm function, sexual desire, sexual satisfaction and overall sexual functioning was 11.98%, 15.14%, 19.7% and 18.46%, respectively. Hemodynamic indices remained stable during the 3-month follow-up; only clinically insignificant decrease in systolic BP by no more than 2 mm Hg during the entire follow-up period was observed. At the same time there was no influence on diastolic BP. Changes in heart rate were also clinically insignificant, averaging no more than 1 beat per minute. Conclusions: The results of observational study allow to recommend Alfuprost® MR as a first-line therapy for BPH, including for sexually active men and patients with various types of sexual dysfunction. Considering minimal and clinically insignificant vasodilatory effects observed during 3 months of therapy, it is possible to prescribe Alfuprost® MR in a dosage of 10 mg once daily, including comorbid patients.

Full Text

Restricted Access

About the authors

D. Yu Pushkar

A.I. Evdokimov Moscow State University of Medicine and Dentistry of Minzdrav of Russia

Ph.D., MD, professor, academician of RAS, Head of the Department of Urology Moscow, Russia

O. B Loran

Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation

Ph.D., MD, professor, academician of RAS, Head of the Department of Urology and Surgical Andrology Moscow, Russia

A. N Bernikov

A.I. Evdokimov Moscow State University of Medicine and Dentistry of Minzdrav of Russia

Ph.D., associate professor Moscow, Russia


  1. Anderson J.B. The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol.2001; 39;390-399.
  2. Donnell R.F. Benign prostate hyperplasia: a review of the year’s progressfrom bench to clinic. Curr Opin Urol. 2011; 21(1):22-26.
  3. Nasu K., Moriyama N., Kawabe K. Et al. Quantification and distribution of a1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non hypertrophied tissue. Br. J. Pharmacol. 1996;119:797-803.
  4. Борисов В.В. Комбинированная терапия а1-адреноблокатором и ингибитором фосфодиэстеразы 5-го типа пациентов с доброкачественной гиперплазией предстательной железы и эректильной дисфункцией: результаты наблюдательного проспективного мультицентрового исследования. Урология. 2020;3:50-55). Doi:
  5. Emberton M., Cornel E.B., Bassi P.F., Fourcade R.O., Gomez J.M.F., Castro R. Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. 2008;62(7):1076-1086. doi: 10.1111/j.1742-1241.2008.01785.x.
  6. Петричко М.И., Волков А.А., 2015 Медикаментозная терапия больных больных доброкачественной гиперплазией предстательной железы - современные подходы. Монография. М., 2015).
  7. Marberger M., Harkaway R., de la Rosette J. Optimizing the medical management of benign prostatic hyperplasia. Eur Urol. 2004; 45: 411-419.
  8. McConnell D. et al. The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia. New England Journal of Medicine. 2003;349(25): 2387-2398. doi: 10.1056/nejmoa030656.
  9. Roehrborn C., Broderick G., Brock G., Elion-Mboussa A., Watts S.,Viktrup L. Once daily tadalafil improved symptoms of benign prostatic hyperplasia in men with or without history of erectile dysfunction. Eur Urol. Supplements 24th Annual EAU Congress Stockholm 17-21 March 2009.
  10. Мартов А.Г., Духанин А.С., Берников А.Н. Актуальные вопросы терапии альфа1-адреноблокаторами: интеграция фармакологического подхода и клинического опыта. Урология. 2022;3:166-175). Doi:
  11. Пушкарь Д.Ю., Раснер П.И. Терапия a-адреноблокаторами у больных ДГПЖ. Лечащий врач. 2007;4:4-10.
  12. Alison M. Mondul, Eric B. Rimm, Edward Giovannucci, Dale B. Glasser, Elizabeth A. Platz. A Prospective Study of Lower Urinary Tract Symptoms and Erectile Dysfunction. J Urol. 2008;179(6):2321-2326. doi: 10.1016/j.juro.2008.01.150.
  13. Descazeaud A., de La Taille A., Giuliano F., Desgrandchamps F., Doridot G. Effetsnegatifssur la sexualite des traitementsmedicamenteux des symptömes du bas appareilurinaireliesal’hypertrophiebenigne de la prostate. Prog Urol. 2015;25(3):115-127.].
  14. Djavan B., et al. Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. Urology. 2004;64:1144.
  15. Mondul A.M., et al. A Prospective Study of Lower Urinary Tract Symptoms and Erectile Dysfunction. J Urol. 2008;179(6):2321-2326. doi: 10.1016/j.juro.2008.01.150.
  16. Elhilali M., Emberton M., Matzkin H. et al. ALF-ONE Study Group. Longterm efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in «real-life» practice. BJU Int. 2006;97(3):513-519.
  17. Yoon S., Choi J. H., Lee S.H., Choi S.M., Jeh S.U., Kam S.C., Hyun J.S. Efficacy of Long-Term Daily Dosage of Alfuzosin 10 mg upon Sexual Function of Benign Prostatic Hypertrophy Patients: Two-Year Prospective Observational Study. The World Journal of Men’s Health. 2014;32(3):133. doi: 10.5534/wjmh.2014.32.3.133.
  18. Sanchez-Chapado M., Guil M., Alfaro V., Badiella L., Fernandez-Hernando N. Safety and Efficacy of Sustained-Release Alfuzosin on Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in 3,095 Spanish Patients Evaluated during General Practice. European Urology. 2000;37(4):421-427. doi: 10.1159/000020163.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies